Drug Trial Radar · NCT00624130
Yasmin 20 Cycle Control - Yasmin 20 Versus Mercilon in Healthy Female Volunteers
Last checked: Nov 20, 2026Latest source record: Dec 31, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
453
Actual
Start
Mar 2004
Primary completion
Not stated
Study completion Jun 2005
Sponsor
- Lead sponsor
- BayerBayer (BAYRY)
- Sponsor type
- Industry
- First posted
- Feb 26, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- Who can join
- Female only, from 18 years, up to 35 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to compare bleeding pattern of contraceptive Yasmin 20 to a marketed comparator.
Conditions
- Contraception
Interventions
Yasmin 20Drug
Yasmin 20, 24-d regimen vs Mercilon, Tablet p.o. (oral)
MercilonDrug
Mercilon, 24-d regimen vs Yasmin 20 , Tablet p.o. (oral)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cycle control and bleeding patternTime frame: 7 cycles
Locations
17 sites in 4 countries. Site status is shown where the registry gives one.
Site not named
Horn, Austria
Site not named
Leibnitz, Styria, Austria
Site not named
Mödling, Austria
Site not named
Sankt Pölten, Austria
Site not named
Vienna, Austria
Site not named
Wörgl, Austria
Site not named
Pärnu, Estonia
Site not named
Talinn, Estonia
Site not named
Tartu, Estonia
Site not named
Helsinki, Finland
Site not named
Helsinki, Finland
Site not named
Tampere, Finland
Site not named
Turku, Finland
Site not named
Kaunas, Lithuania
Site not named
Kaunas, Lithuania
Site not named
Vilnius, Lithuania
Site not named
Vilnius, Lithuania
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.